Vanguard Tax Managed Fund FTSE Developed Markets ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.25, while GeneDx Holdings Corp trades at $82.44 (market cap $2.44B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| VEA | WGS | |
|---|---|---|
52-Week High | $72.89 | $167.51 |
52-Week Low | $58.19 | $34.51 |
Market Cap | — | $2.44B |
Sector | — | Technology |
Enterprise Value | — | $2.48B |
Signals from Pluang's Aura AI — not financial advice
VEA trades at $73.31, up 1.12% with a bullish technical signal from moving averages. The ETF shows mixed institutional activity with both new acquisitions and position reductions. Recent news highlights VEA's competitive advantages in expense ratios and international diversification compared to peers like SPGM and NZAC.
Outlook remains positive given strong technical momentum and cost advantages, though overbought RSI signals near-term caution. Key risks include international market volatility and currency fluctuations. The ETF's low-cost structure and developed market exposure provide long-term diversification benefits for US investors.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Trailing returns across standard periods
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →